Table 1.
Basic characteristics.
| Author | Sample size | Country | Age | male/female | Cancer | Treatment other than surgery | TIGIT+ expression | Expression location | Cutoff value of TIGIT | Outcome | Method to estimate HR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhao JJ (2018) |
154 | China | 55 (37–48) | (124/30) | ESCC | Not available | 76 (49.4%) | TIL | Median level | OS | Multivariate |
| Tang W(2019) | 441 | China | (<62:159, ≥62:282) | (245/196) | GC | Adjuvant chemotherapy | 343 (77.8%) | Tumor cell | ≥5% positivity cell | OS | Multivariate |
| Xu Y(2019) | 60 | China | (≤60:34,>60:26) | (43/17) | SCLC | Adjuvant chemotherapy | 21 (35%) | Tumor cell | Median level | OS | Univariate |
| Lee WJ (2020) |
124 | Korea | 61.8(25-89) | (68/56) | Melanoma | Not available | 52 (41.9%) | Tumor cell | ≥20% positivity cell | OS/PFS | Univariate |
| Sun Y (2020) |
334 | China | 56(28-81) | (182/152) | NSCLC | Not available | 204 (61.1%) | TIL | ≥5% positivity cell | OS/PFS | Multivariate |
| Zhao K (2020) |
114 | China | ≤60 76, >60 38 | (84/30) | PSCCE | Adjuvant chemotherapy/chemoradiotherapy. | 74 (64.9%) | Tumor cell | ≥5% positivity cell | OS/PFS | Multivariate |
| Zhou X (2020) |
60 | China | ≤60 34, >60 26 | (35/25) | CRC | Not available | 21 (35%) | Tumor cell | CPS≥1 | OS/DFS | Multivariate |
| Liang R(2021) | 139 | China | ≤45:25, >45 114 | (82/57) | CRC | Not available | 40 (28.8%) | Tumor cell | Median level | OS/RFS | Univariate |
| Liu HF (2022) |
194 | China | 56 ± 12.66 | (135/59) | GC | Adjuvant chemotherapy | 97(50%) | TIL | Median level | OS | Multivariate |
| Peipei Wang (2021) |
95 | China | 58 ± 10 | (81/14) | ESCC | Not available | 68(72%) | Tumor cell | Median level | OS | Multivariate |
| Daisuke Murakami(2022) | 100 | Japan | > 70 53 (53%); < 70 years 47 (47%) | (55/45) | CRC | Not available | 79(79%) | TIL | ≥10% positivity cell | OS | Multivariate |
| Jiang C (2022) |
81 | China | 63(29–81) | (68/13) | NSCLC | Not available | 33 (40.7%) | TIL | CPS≥1 | OS | Multivariate |
| Yu LH (2021) |
133 | China | 58.3 ± 11.4 | (103/30) | HBV-HCC | Adjuvant immunotherapy ± adjuvant chemotherapy | 65(48.87%) | TIL | Median level | PFS | Multivariate |
| Shi X (2021) |
200 | China | 49 (12–80) | (105/95) | MTC | Not available | 6 (3.0%) | Tumor cell | CPS≥1 | OS/RFS | Univariate |
| Liu ZP (2020) |
141 | China | ZSHC cohort 62(56-71);FUSCC cohort 62(56-68) | ZSHC cohort (117/24);FUSCC cohort(102/16) | MIBC | Adjuvant chemotherapy | ZSHC cohort46(32.62%);FUSCC cohort 68(57.63%) | TIL | Median level | OS/RFS | Multivariate |
| Luo Y (2022) |
234 | China | 55.50 (41.25, 66.50) | 112(47.86%) | TC | Not available | 37(15.81%) | Tumor cell and TIL | CPS≥1 | OS/DFS | Multivariate |